Answers are grounded in this paper and cite their sources.
Radiolabeled folate derivatives have been extensively investigated for positron emission tomography (PET) imaging of ovarian cancer due to the frequent overexpression of folate receptor (FR).However, clinical translation has been hindered, at least in part, by suboptimal tumor uptake of FR-targeted radiotracers.In this study, we developed and characterized a 68 Ga-labeled heterodimeric radiotracer, 68 Ga-folate-KR, designed to concurrently target FR and human epidermal growth factor receptor 2 (HER2), another receptor commonly overexpressed in ovarian cancer.Transcriptomics analysis confirmed the co-upregulation of FOLR1 and HER2 in ovarian cancer tissues relative to normal ovarian tissue, supporting the rationale for dual-receptor targeting.In vitro binding assays demonstrated specific binding of 68 Ga-folate-KR to both receptors.PET imaging and biodistribution studies in SKOV3 tumor-bearing mice revealed significantly enhanced tumor uptake and improved tumor-to-nontumor contrast compared to the monomeric radiotracers 68 Ga-folate and 68 Ga-KR.Competitive blocking experiments further confirmed the in vivo dual-receptor targeting capability of 68 Ga-folate-KR.Collectively, our results highlight that 68 Ga-folate-KR enables more sensitive PET detection of ovarian cancer xenografts.With further optimization, dual-receptor-targeted radiotracers hold promise for clinical translation in both lesion detection and therapy response monitoring in ovarian cancer.
No takes yet. Share an insight, caveat, or question.
Xiaodan Shi (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: